ShockWave Medical, Inc. (SWAV)
$198.62
+7.45 (+3.90%)
Rating:
Recommendation:
-
| Symbol | SWAV |
|---|---|
| Price | $198.62 |
| Beta | 1.485 |
| Volume Avg. | 0.65M |
| Market Cap | 7.109B |
| Shares () | - |
| 52 Week Range | 113.36-249.73 |
| 1y Target Est | - |
| DCF Unlevered | SWAV DCF -> | |
|---|---|---|
| DCF Levered | SWAV LDCF -> | |
| ROE | 12.36% | Buy |
| ROA | 7.78% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 39.09% | Neutral |
| P/E | 239.30 | Strong Buy |
| P/B | 26.39 | Strong Buy |
Latest SWAV news
About
Download (Excel)Mr. Douglas Godshall
Healthcare
Medical Devices
NASDAQ Global Select
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.